CLAIMS

1. A composition comprising Torasemide, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin or Bromocriptine, or a salt, prodrug, derivative, or sustained release formulation thereof, for use in the treatment of a neurological disorder in a subject in need thereof.

2. The composition of claim 1, further comprising at least one distinct compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine or Torasemide, or a salt, prodrug, derivative, or sustained release formulation thereof.

3. The composition of claim 2, wherein said composition comprises at least one of the following combinations of compounds:
   - Baclofen and Torasemide,
   - Sulfisoxazole and Torasemide,
   - Eplerenone and Torasemide,
   - Acamprosate and Ifenprodil,
   - Baclofen and Mexiletine,
   - Baclofen and Trimetazidine,
   - Bromocriptine and Sulfisoxazole,
   - Cinacalcet and Mexiletine,
   - Cinnarizine and Trimetazidine,
   - Trimetazidine and Zonisamide,
   - Levosimendan and Mexiletine,
   - Levosimendan and Ifenprodil,
   - Levosimendan and Trimetazidine,
   - Levosimendan and Moxifloxacin,
   - Terbinafine and Torasemide,

- Moxifloxacin and Trimetazidine,
- Moxifloxacin and Ifenprodil,
- Ifenprodil and Cinnarizine,
- Moxifloxacin and Baclofen,
- Moxifloxacin and Cinacalcet,
- Moxifloxacin and Zonisamide,
- Moxifloxacin and Sulfisoxazole,
- Mexiletine and Ifenprodil,
- Ifenprodil and Cinnarizine, Baclofen and Trimetazidine and Torasemide,
- Baclofen and Cinacalcet and Torasemide,
- Baclofen and Acamprosate and Torasemide,
- Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,
- Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,
- Baclofen and Acamprosate and Torasemide and Diethylcarbamazine,
- Baclofen and Acamprosate and Torasemide and Ifenprodil,
- Levosimendan and Baclofen and Trimetazidine,
- Levosimendan and Aminocaproic acid and Trimetazidine,
- Levosimendan and Terbinafine and Trimetazidine, or
- Levosimendan and Sulfisoxazole and Trimetazidine.

4. The composition of any one of the preceding claims, which further comprises a pharmaceutically acceptable carrier or excipient.

5. The composition of any one of the preceding claims, wherein the neurological disorder is selected from Alzheimer's disease, Alzheimer's related diseases, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

6. The composition of any one of the preceding claims, wherein the compounds in said composition are formulated or administered together, separately or sequentially.

7. The composition of any one of the preceding claims, wherein said composition is administered repeatedly to the subject.

8. A composition comprising at least one first compound selected from the group consisting of Torasemide, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, Bromocriptine, and salt(s), prodrug(s), derivative(s), or sustained release formulation(s) thereof, in combination with at least one second compound distinct from said first compound, selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Bromocriptine, Ifenprodil, Torasemide, and Moxifloxacin salt(s), prodrug(s), derivative(s), or sustained release formulation(s) thereof, and a pharmaceutically acceptable excipient for simultaneous, separate or sequential administration.

9. The composition of claim 8, wherein said composition comprises at least one of the following combinations of compounds:
   - Baclofen and Torasemide,
   - Sulfisoxazole and Torasemide,
   - Eplerenone and Torasemide,
   - Acamprosate and Ifenprodil,
   - Baclofen and Mexiletine,
   - Baclofen and Trimetazidine,
   - Bromocriptine and Sulfisoxazole,
   - Cinacalcet and Mexiletine,
   - Cinnarizine and Trimetazidine,
   - Trimetazidine and Zonisamide,
   - Levosimendan and Mexiletine,
   - Levosimendan and Ifenprodil,
   - Levosimendan and Trimetazidine,
   - Levosimendan and Moxifloxacin,

- Terbinafine and Torasemide,
- Moxifloxacin and Trimetazidine,
- Moxifloxacin and Ifenprodil,
- Moxifloxacin and Baclofen,
- Moxifloxacin and Cinacalcet,
- Moxifloxacin and Zonisamide,
- Moxifloxacin and Sulfisoxazole,
- Mexiletine and Ifenprodil,
- Ifenprodil and Cinnarizine,
- Baclofen and Trimetazidine and Torasemide,
- Baclofen and Cinacalcet and Torasemide,
- Baclofen and Acamprosate and Torasemide,
- Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,
- Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,
- Baclofen and Acamprosate and Torasemide and Diethylcarbamazine,
- Baclofen and Acamprosate and Torasemide and Ifenprodil,
- Levosimendan and Baclofen and Trimetazidine,
- Levosimendan and Aminocaproic acid and Trimetazidine,
- Levosimendan and Terbinafine and Trimetazidine, or
- Levosimendan and Sulfisoxazole and Trimetazidine.

CLAIMS

1. The use of a composition comprising Torasemide or a salt, or sustained release formulation thereof, for the manufacture of a medicament for treating Alzheimer's disease (AD) or an AD related disorder, amyotrophic lateral sclerosis (ALS) or spinal cord injury (SCI).

2. The use according to claim 1, wherein said medicament further comprises a composition comprising at least one compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Levosimendan, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Ifenprodil, Moxifloxacin, or Bromocriptine, Torasemide, or salt(s), or sustained release formulation(s) thereof.

3. The use according to any one of the preceding claims, wherein said medicament comprises at least one of the following combinations of compounds:
   - Baclofen and Torasemide,
   - Sulfisoxazole and Torasemide,
   - Eplerenone and Torasemide,
   - Terbinafine and Torasemide,
   - Baclofen and Trimetazidine and Torasemide,
   - Baclofen and Cinacalcet and Torasemide,
   - Baclofen and Acamprosate and Torasemide,
   - Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,
   - Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,
   - Baclofen and Acamprosate and Torasemide and Diethylcarbamazine, or
   - Baclofen and Acamprosate and Torasemide and Ifenprodil,
   - or salt(s), or sustained release formulation(s) thereof.

4. The use according to any one of the preceding claims, wherein said compositions further comprise a pharmaceutically acceptable carrier or excipient.

5. The use according to any one of claims 2 to 4, wherein the compounds in said medicament are formulated together or separately.

6. The use of any one of the preceding claims, wherein said composition(s) is (are) formulated to be administered repeatedly to the subject.

7. A composition comprising Torasemide or salt(s), or sustained release formulation(s) thereof, in combination with at least one second compound selected from Sulfisoxazole, Methimazole, Prilocaine, Dyphylline, Quinacrine, Carbenoxolone, Acamprosate, Aminocaproic acid, Baclofen, Cabergoline, Diethylcarbamazine, Cinacalcet, Cinnarizine, Eplerenone, Fenoldopam, Leflunomide, Sulodexide, Terbinafine, Zonisamide, Etomidate, Phenformin, Trimetazidine, Mexiletine, Bromocriptine, Ifenprodil, and Moxifloxacin, or salt(s) or sustained release formulation(s) thereof, and a pharmaceutically acceptable excipient.

8. The composition of claim 7, wherein said composition comprises at least one of the following combinations of compounds:
   - Baclofen and Torasemide,
   - Sulfisoxazole and Torasemide,
   - Eplerenone and Torasemide,
   - Terbinafine and Torasemide,
   - Baclofen and Trimetazidine and Torasemide,
   - Baclofen and Cinacalcet and Torasemide,
   - Baclofen and Acamprosate and Torasemide,
   - Sulfisoxazole and Trimetazidine and Torasemide and Zonisamide,
   - Sulfisoxazole and Mexiletine and Torasemide and Cinacalcet,
   - Baclofen and Acamprosate and Torasemide and Diethylcarbamazine, or
   - Baclofen and Acamprosate and Torasemide and Ifenprodil,

or salt(s) or sustained release formulation(s) thereof; and a pharmaceutically acceptable excipient.